DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for microcephaly-micromelia syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMicrocephaly-micromelia syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for microcephaly-micromelia syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The 2011 study found that the Angelman syndrome protein UBE3A interacts with the primary microcephaly protein ASPM and localises to centrosomes. In HEK293 cells, shRNA knockdown of UBE3A caused mitotic abnormalities including chromosome missegregation, abnormal cytokinesis and apoptosis. The authors note that more than 80% of Angelman syndrome patients have microcephaly, but that unlike in primary microcephaly, the microcephaly in Angelman syndrome is postnatal. No drug or intervention was tested.
A 2017 study reports that mutations in KIF14, encoding a kinesin-like protein, cause both primary and syndromic microcephaly. The majority of known microcephaly genes encode proteins implicated in cell division and many localise to the centrosome. No treatment is discussed.
A 1996 case report describes a male child with "apple peel" intestinal atresia, microcephaly, hydrocephalus, short stature, moderate global developmental delay and ocular abnormalities. The authors consider this a distinct syndromic entity. A 2021 clinical case report discusses orofacial manifestations in two children with severe microcephaly, noting similar facial and occlusion patterns, and suggests future studies on preventive and interceptive therapeutics. No drug is mentioned in either report.
What is missing is any clinical trial of a drug for microcephaly-micromelia syndrome, any patient stratification by genotype, and any funding for such work. The basic biology points to centrosome and mitotic defects, but no compound has been tested in patients or animal models of this specific syndrome.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PLoS ONE · 2011 · 33 citations · open access
Angelman Syndrome Protein UBE3A Interacts with Primary Microcephaly Protein ASPM, Localizes to Centrosomes and Regulates Chromosome Segregation
AbstractMany proteins associated with the phenotype microcephaly have been localized to the centrosome or linked to it functionally. All the seven autosomal recessive primary microcephaly (MCPH) proteins localize at the centrosome. Microcephalic osteodysplastic primordial dwarfism type II protein PCNT and Seckel syndrome (also characterized by severe microcephaly) protein ATR are also centrosomal proteins. All of the above findings show the importance of centrosomal proteins as the key players in neurogenesis and brain development. However, the exact mechanism as to how the loss-of-function of these proteins leads to microcephaly remains to be elucidated. To gain insight into the function of the most commonly mutated MCPH gene ASPM, we used the yeast two-hybrid technique to screen a human fetal brain cDNA library with an ASPM bait. The analysis identified Angelman syndrome gene product UBE3A as an ASPM interactor. Like ASPM, UBE3A also localizes to the centrosome. The identification of UBE3A as an ASPM interactor is not surprising as more than 80% of Angelman syndrome patients have microcephaly. However, unlike in MCPH, microcephaly is postnatal in Angelman syndrome patients. Our results show that UBE3A is a cell cycle regulated protein and its level peaks in mitosis. The shRNA knockdown of UBE3A in HEK293 cells led to many mitotic abnormalities including chromosome missegregation, abnormal cytokinesis and apoptosis. Thus our study links Angelman syndrome protein UBE3A to ASPM, centrosome and mitosis for the first time. We suggest that a defective chromosome segregation mechanism is responsible for the development of microcephaly in Angelman syndrome.
International Journal of Paediatric Dentistry · 2002 · 31 citations
Riga–Fede disease: association with microcephaly
AbstractA case of microcephaly associated with traumatic ulceration to the ventral surface of the tongue (Riga-Fede disease) in a 12-month-old female is presented. To the best of our knowledge, such association has not been described previously. A conservative treatment regime was used, involving medical management, elimination of the sharp edges of the teeth and use of topical triamcinolone, and the ulceration healed over a period of 4 weeks.
Further evidence for a syndrome of “apple peel” intestinal atresia, ocular anomalies and microcephaly
AbstractWe report on a male child with "apple peel" atresia, associated with microcephaly, with subsequent hydrocephalus, short stature, moderate global developmental delay and ocular abnormalities. A similar phenotype was previously reported by Stromme et al. in 1993 in female siblings, and this description of another affected individual provides further evidence for this being a distinct syndromic entity.
European Journal of Dental and Oral Health · 2021 · 1 citations · open access
Correlation of Facial, Dental and Oral Functions of Children with Microcephaly: Clinical Case Report
AbstractThis paper discusses the orofacial manifestations of children diagnosed with severe microcephaly according to the World Health Organization. Microcephaly is a clinical condition made at or after birth that characterizes a significant reduction in head circumference, which may present craniofacial, neurological, and oral alterations as a result of this malformation. As skull growth is linked to facial growth, can patients with microcephaly have structural and functional impairments? Will these possible changes be expressed before skeletal maturity? These issues are discussed through the presentation of two relevant clinical reports of children diagnosed with severe microcephaly with similar clinical facial and occlusion patterns.. Studies along these lines should be conducted with a view to future attempts to minimize possible effects of this malformation on the craniofacial complex with preventive and interceptive therapeuticals in these individuals.
Mutations in KIF14, Encoding Kinesin-Like Protein KIF14, Cause Primary and Syndromic Microcephaly
AbstractPrimary microcephaly (small head) is a neurodevelopmental disorder characterized by a reduction in the size of the cerebral cortex accompanied with mild to moderate intellectual disability. This condition is observed either as an isolated form referred to as autosomal recessive primary microcephaly (MCPH) or in combination with additional features like growth retardation, renal and cranio-facial abnormalities or others subsumed under syndromic microcephaly. Both MCPH and syndromic microcephaly are heterogeneous disorders caused by mutations of many different genes. The majority of these genes encode proteins implicated in cell division and many of them have been localized at the centrosome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
